Dendritic cell-based vaccines: clinical applications in breast cancer

Papers of special note have highlighted as:

•of interest

••of considerable interest

References

• 1 Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol. Ther. 99(1), 113–132 (2003).
  Medline CASGoogle Scholar
• 2 Andre F, Dieci MV, Dubsky P et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin. Cancer Res. 19(1), 28–33 (2013).
  Medline CASGoogle Scholar
• 3 Yaguchi T, Sumimoto H, Kudo-Saito C. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93(3), 294–300 (2011).
  MedlineGoogle Scholar
• 4 Zheng J, Liu Q, Yang J et al. Co-culture of apoptotic breast cancer cells with immature dendritic cells: a novel approach for DC-based vaccination in breast cancer. Braz. J. Med. Biol. Res. 45(6), 510–515 (2012).
  Medline CASGoogle Scholar
• 5 Penn I. Tumors of the immunocompromised patient. Annu. Rev. Med. 39, 63–73 (1998).
  Google Scholar
• 6 Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20(4), 538–549 (2011).
  Medline CASGoogle Scholar
• 7 DeNardo DG, Barreto JB, Andreu P et al. CD4⁽⁺⁾ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2), 91–102 (2009).
  Medline CASGoogle Scholar
• 8 Bidwell BN, Slaney CY, Withana NP et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18(8), 1224–1231 (2012).
  Medline CASGoogle Scholar
• 9 Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 110(8), 1677–1686 (2007).
  Medline CASGoogle Scholar
• 10 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012). • The activity and safety of BMS-936558, an antibody that specifically blocks PD-1, was assessed in 296 patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, renal cell cancer or colorectal cancer. Objective responses were recorded in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer.
  Medline CASGoogle Scholar
• 11 Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur. J. Cancer 49(14), 2965–2967 (2013).
  Medline CASGoogle Scholar
• 12 Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol. 25(3), 396–402 (2013).
  Medline CASGoogle Scholar
• 13 Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr. Opin. Oncol. 25(6), 602–608 (2013). •• Broad summary of the literature illustrating the immune approaches that should be evaluated in the treatment of breast cancer (BC).
  Medline CASGoogle Scholar
• 14 Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumour escape. Nat. Immunol. 3(11), 991–998 (2002).
  Medline CASGoogle Scholar
• 15 Curigliano G. Immunity and autoimmunity: revising the concepts of response to breast cancer. Breast 20(3), 71–74 (2011).
  MedlineGoogle Scholar
• 16 Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411(6835), 380–384 (2001).
  Medline CASGoogle Scholar
• 17 Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2(6), 847–862 (2010). •• Detailed review explaining the use of dendritic cells (DCs) in immunotherapy.
  CASGoogle Scholar
• 18 Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685–711(2003).
  Medline CASGoogle Scholar
• 19 Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515–1525 (2004).
  Medline CASGoogle Scholar
• 20 Nencioni A, Grünebach F, Schmidt SM et al. The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65(3), 191–199 (2008). • Includes a complete description of DC biology and methods of vaccination, as well as discussion about clinical application.
  MedlineGoogle Scholar
• 21 Ma Y, Shurin GV, Peiyuan Z et al. Dendritic cells in the cancer microenvironment. J. Cancer 4(1), 36–44 (2013).
  Medline CASGoogle Scholar
• 22 Engelhardt JJ, Boldajipour B, Beemiller P et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21(3), 402–417 (2012).
  Medline CASGoogle Scholar
• 23 Mu CY, Huang JA, Chen Y et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28 (3), 682–688 (2011).
  Medline CASGoogle Scholar
• 24 Eisenbarth SC, Williams A, Colegio OR et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 484(7395), 510–513 (2012).
  Medline CASGoogle Scholar
• 25 Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53(6), 510–518 (2004) • Indicates the impaired immunological function of DCs of breast cancer patients compared with normal subjects.
  MedlineGoogle Scholar
• 26 Banchereau J, Schuler-Thurner B, Palucka AK et al. Dendritic cells as vectors for therapy. Cell 106(3), 271–274 (2001).
  Medline CASGoogle Scholar
• 27 Lee AW, Truong T, Bickham K et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte- derived dendritic cells: implications for immunotherapy. Vaccine 20 (4), 8–22 (2002).
  Google Scholar
• 28 Ballestrero A, Boy D, Moran E et al. Immunotherapy with dendritic cells for cancer. Adv. Drug Deliv. Rev. 60(2), 173–183 (2008).
  Medline CASGoogle Scholar
• 29 Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev. 39(8), 879–885 (2013).
  Medline CASGoogle Scholar
• 30 Khattak M, Fisher R, Turajlic S et al. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther. Adv. Med. Oncol. 5(2), 105–118 (2013).
  Medline CASGoogle Scholar
• 31 Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann. Oncol. 23(8), 35–40 (2012).
  Google Scholar
• 32 Rini BI, Stein M, Shannon P et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758–767 (2011).
  Medline CASGoogle Scholar
• 33 Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 19(4), 365–370 (2013).
  Medline CASGoogle Scholar
• 34 Cheever MA.. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011). •• Sipuleucel-T (PROVENGE®, Dendreon) is the first therapeutic cancer vaccine to be approved by the US FDA.
  MedlineGoogle Scholar
• 35 Lissoni P, Vigore L, Ferranti R et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents 13(4), 216–219 (1999).
  Medline CASGoogle Scholar
• 36 Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95(16), 9482–9487 (1998).
  Medline CASGoogle Scholar
• 37 Wright SE. Immunotherapy of breast cancer. Expert Opin. Biol. Ther. 12, 479–490 (2012).
  Medline CASGoogle Scholar
• 38 Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human DCs and breast carcinoma cells. Proc. Natl Acad. Sci. USA 97(6), 2715–2718 (2000).
  Medline CASGoogle Scholar
• 39 Neidhardt-berard EM, Berard F, Banchereau J et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 6(4), 322–328 (2004).
  Google Scholar
• 40 Wang B, Zaidi N, He LZ et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res. 14, R39 (2012).
  Medline CASGoogle Scholar
• 41 Wang L, Xie Y, Ahmed KA et al. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice. Breast Cancer Res. Treat. 140(2), 273–284 (2013).
  Medline CASGoogle Scholar
• 42 Sakai Y, Morrison BJ, Burke JD et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64(21), 8022–8028 (2004).
  Medline CASGoogle Scholar
• 43 Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine 29(29–30), 4785–4793 (2011).
  Medline CASGoogle Scholar
• 44 Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102–2108 (2000).
  Medline CASGoogle Scholar
• 45 Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699–4708 (2004).
  Medline CASGoogle Scholar
• 46 Qi CJ, Ning YL, Han YS et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol. Immunother. 61(9), 1415–1424 (2012).
  Medline CASGoogle Scholar
• 47 Baek S, Kim CS, Kim SB et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a Phase I/II trial. J. Transl. Med. 20, 9–178 (2011). •• First trial to evaluate the safety and efficacy of the combination of IL-2 and DC vaccine.
  Google Scholar
• 48 www.clinicaltrials.gov
  Google Scholar
• 49 Cui Y, Yang X, Zhu W et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol. Lett. 6(2), 537–541 (2013).
  MedlineGoogle Scholar
• 50 Ren J, Di L, Song G et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin. Transl. Oncol. 15(10), 780–788. (2013).
  Medline CASGoogle Scholar
• 51 Finn OJ, Forni G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14(2), 172–177 (2002).
  Medline CASGoogle Scholar
• 52 Koski GK, Koldovsky U, Xu S et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35(1), 54–65 (2012).
  Medline CASGoogle Scholar
• 53 Czerniecki BJ, Koski GK, Koldovsky U et al . Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67(4), 1842–1852 (2007).
  Medline CASGoogle Scholar
• 54 Sharma A, Koldovsky U, Xu S et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118(17), 4354–4362 (2012).
  Medline CASGoogle Scholar
• 55 Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
  Medline CASGoogle Scholar
• 56 Galluzzi L, Senovilla L, Vacchelli E et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 1(7), 1111–1134 (2012).
  MedlineGoogle Scholar
• 57 Strasser EF, Eckstein R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus. Med. Rev. 24(2), 130–139 (2010).
  MedlineGoogle Scholar
• 58 Dikov MM, Ohm JE, Ray N. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174, 215–222 (2005).
  Medline CASGoogle Scholar
• 59 Kawakami Y, Yaguchi T, Sumimoto H et al. Improvement of cancer immunotherapy by combining molecular targeted therapy. Front. Oncol. 3, 136 (2013).
  MedlineGoogle Scholar
• 60 Tacken PJ, de Vries IJ, Torensma R et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790–802 (2007).
  Medline CASGoogle Scholar
• 61 Sancho D, Mourão-Sá D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118, 2098–2110 (2008).
  Medline CASGoogle Scholar
• 62 Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8⁺ T cell tolerance. J. Exp. Med. 196, 1627–1638 (2002).
  Medline CASGoogle Scholar
• 63 Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779 (2001).
  Medline CASGoogle Scholar
• 64 Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4 (10), 762–774 (2004).
  Medline CASGoogle Scholar
• 65 Zheng X, Koropatnick J, Chen D et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int. J. Cancer 132(4), 967–977 (2013).
  Medline CASGoogle Scholar
• 66 Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care (Basel) 7(4), 262–266 (2012).
  MedlineGoogle Scholar
• 67 Van Tendeloo VF, Ponsaerts P, Berneman ZN. mRNA based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 9, 423–431 (2007).
  Medline CASGoogle Scholar
• 68 Zhang B, Beeghly-Fadiel A, Long J, Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 12(5), 477–488 (2011).
  Medline CASGoogle Scholar
• 69 Vonderheide RH, LoRusso PM, Khalil M. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16(13), 3485–3494 (2010).
  Medline CASGoogle Scholar
• 70 Hodi FS, Butler M, Oble DA. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105(8), 3005 (2008).
  Medline CASGoogle Scholar
• 71 Zitvogel L, Apetoh L, Ghiringhelli, F et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).
  Medline CASGoogle Scholar
• 72 Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
  Medline CASGoogle Scholar
• 73 Stagg J, Andre F, Loi S. Immunomodulation via chemotherapy and targeted therapy: a new paradigm in breast cancer therapy? Breast Care (Basel) 7(4), 267–272 (2012). • Discusses the underlying mechanisms of how cytotoxic chemotherapy can stimulate an antitumor immune response and how combinations of traditional agents with new immunotherapeutic therapies may significantly advance our treatment of breast cancer.
  MedlineGoogle Scholar